Selective gene-expression profiling of migratory tumor cells in vivo predicts clinical outcome in breast cancer patients

IntroductionMetastasis of breast cancer is the main cause of death in patients. Previous genome-wide studies have identified gene-expression patterns correlated with cancer patient outcome. However, these were derived mostly from whole tissue without respect to cell heterogeneity. In reality, only a small subpopulation of invasive cells inside the primary tumor is responsible for escaping and initiating dissemination and metastasis. When whole tissue is used for molecular profiling, the expression pattern of these cells is masked by the majority of the noninvasive tumor cells. Therefore, little information is available about the crucial early steps of the metastatic cascade: migration, invasion, and entry of tumor cells into the systemic circulation.MethodsIn the past, we developed an in vivo invasion assay that can capture specifically the highly motile tumor cells in the act of migrating inside living tumors. Here, we used this assay in orthotopic xenografts of human MDA-MB-231 breast cancer cells to isolate selectively the migratory cell subpopulation of the primary tumor for gene-expression profiling. In this way, we derived a gene signature specific to breast cancer migration and invasion, which we call the Human Invasion Signature (HIS).ResultsUnsupervised analysis of the HIS shows that the most significant upregulated gene networks in the migratory breast tumor cells include genes regulating embryonic and tissue development, cellular movement, and DNA replication and repair. We confirmed that genes involved in these functions are upregulated in the migratory tumor cells with independent biological repeats. We also demonstrate that specific genes are functionally required for in vivo invasion and hematogenous dissemination in MDA-MB-231, as well as in patient-derived breast tumors. Finally, we used statistical analysis to show that the signature can significantly predict risk of breast cancer metastasis in large patient cohorts, independent of well-established prognostic parameters.ConclusionsOur data provide novel insights into, and reveal previously unknown mediators of, the metastatic steps of invasion and dissemination in human breast tumors in vivo. Because migration and invasion are the early steps of metastatic progression, the novel markers that we identified here might become valuable prognostic tools or therapeutic targets in breast cancer.

[1]  B. Ross,et al.  Molecular Imaging of TGFβ-Induced Smad2/3 Phosphorylation Reveals a Role for Receptor Tyrosine Kinases in Modulating TGFβ Signaling , 2011, Clinical Cancer Research.

[2]  Paula D. Bos,et al.  Metastasis: from dissemination to organ-specific colonization , 2009, Nature Reviews Cancer.

[3]  Pierre Nassoy,et al.  MT1-MMP-Dependent Invasion Is Regulated by TI-VAMP/VAMP7 , 2008, Current Biology.

[4]  P. Heikkilä,et al.  Tumorigenesis and Neoplastic Progression An Extensive Tumor Array Analysis Supports Tumor Suppressive Role for Nucleophosmin in Breast Cancer , 2011 .

[5]  W. Muller,et al.  Conditional Deletion of Shp2 in the Mammary Gland Leads to Impaired Lobulo-alveolar Outgrowth and Attenuated Stat5 Activation* , 2006, Journal of Biological Chemistry.

[6]  Jeffrey M. Rosen,et al.  Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features , 2009, Proceedings of the National Academy of Sciences.

[7]  C. Heldin,et al.  The regulation of TGFβ signal transduction , 2009, Development.

[8]  R. Eils,et al.  Systemic spread is an early step in breast cancer. , 2008, Cancer cell.

[9]  Kakajan Komurov,et al.  Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes , 2010, Proceedings of the National Academy of Sciences.

[10]  J. Segall,et al.  Coordinated regulation of pathways for enhanced cell motility and chemotaxis is conserved in rat and mouse mammary tumors. , 2007, Cancer research.

[11]  G. Stamatoyannopoulos,et al.  FKLF, a Novel Krüppel-Like Factor That Activates Human Embryonic and Fetal β-Like Globin Genes , 1999, Molecular and Cellular Biology.

[12]  John S. Condeelis,et al.  Chemotaxis in cancer , 2011, Nature Reviews Cancer.

[13]  C. Caldas,et al.  Molecular classification and molecular forecasting of breast cancer: ready for clinical application? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Jeffrey Wyckoff,et al.  Probing the Microenvironment of Mammary Tumors Using Multiphoton Microscopy , 2006, Journal of Mammary Gland Biology and Neoplasia.

[15]  W. Qi,et al.  NSC348884, a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis in human cancer cells , 2008, Oncogene.

[16]  E. Sahai,et al.  Imaging amoeboid cancer cell motility in vivo , 2008, Journal of microscopy.

[17]  E. Bottinger,et al.  Gene expression analysis on small numbers of invasive cells collected by chemotaxis from primary mammary tumors of the mouse , 2003, BMC biotechnology.

[18]  R. Harland,et al.  Dazap2 is required for FGF-mediated posterior neural patterning, independent of Wnt and Cdx function. , 2009, Developmental biology.

[19]  Vandana Iyer,et al.  Estrogen promotes ER-negative tumor growth and angiogenesis through mobilization of bone marrow-derived monocytes. , 2012, Cancer research.

[20]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[21]  C. Cordon-Cardo,et al.  A multigenic program mediating breast cancer metastasis to bone. , 2003, Cancer cell.

[22]  D. Laune,et al.  Oestrogen receptor negative breast cancers exhibit high cytokine content , 2007, Breast Cancer Research.

[23]  Erik Sahai,et al.  Localised and reversible TGFβ signalling switches breast cancer cells from cohesive to single cell motility , 2009, Nature Cell Biology.

[24]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[25]  Y. Okada,et al.  Recruitment of phosphorylated NPM1 to sites of DNA damage through RNF8-dependent ubiquitin conjugates. , 2010, Cancer research.

[26]  Y. Agazie,et al.  SHP2 is up‐regulated in breast cancer cells and in infiltrating ductal carcinoma of the breast, implying its involvement in breast oncogenesis , 2008, Histopathology.

[27]  Mark T. W. Ebbert,et al.  Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes , 2011, Nature Medicine.

[28]  S. Sleijfer,et al.  Medical oncology: clinical value of circulating tumor cells in breast cancer. , 2011, Nature Reviews Clinical Oncology.

[29]  F. Modugno,et al.  Identification of invasion specific splice variants of the cytoskeletal protein Mena present in mammary tumor cells during invasion in vivo , 2008, Clinical & Experimental Metastasis.

[30]  Jeffrey W Pollard,et al.  Gene Expression Analysis of Macrophages That Facilitate Tumor Invasion Supports a Role for Wnt-Signaling in Mediating Their Activity in Primary Mammary Tumors , 2009, The Journal of Immunology.

[31]  Jeffrey Wyckoff,et al.  Invasion of human breast cancer cells in vivo requires both paracrine and autocrine loops involving the colony-stimulating factor-1 receptor. , 2009, Cancer research.

[32]  M. Barcellos-Hoff,et al.  TGF-beta biology in mammary development and breast cancer. , 2011, Cold Spring Harbor perspectives in biology.

[33]  Clifford A. Meyer,et al.  MYC regulation of a “poor-prognosis” metastatic cancer cell state , 2010, Proceedings of the National Academy of Sciences.

[34]  Alex E. Lash,et al.  Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..

[35]  Robert A. Weinberg,et al.  Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. , 2008, Developmental cell.

[36]  John S. Condeelis,et al.  Identification and Testing of a Gene Expression Signature of Invasive Carcinoma Cells within Primary Mammary Tumors , 2004, Cancer Research.

[37]  R. Andrews,et al.  Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice , 2011, Nature Genetics.

[38]  B. Falini,et al.  Acute myeloid leukemia with mutated nucleophosmin (NPM1): any hope for a targeted therapy? , 2011, Blood reviews.

[39]  A. Vincent-Salomon,et al.  A New Model of Patient Tumor-Derived Breast Cancer Xenografts for Preclinical Assays , 2007, Clinical Cancer Research.

[40]  D. Melton,et al.  "Stemness": Transcriptional Profiling of Embryonic and Adult Stem Cells , 2002, Science.

[41]  R. Puri,et al.  Gene expression in human embryonic stem cell lines: unique molecular signature. , 2004, Blood.

[42]  T. Matozaki,et al.  Protein tyrosine phosphatase SHP‐2: A proto‐oncogene product that promotes Ras activation , 2009, Cancer science.

[43]  D. Waugh,et al.  The Interleukin-8 Pathway in Cancer , 2008, Clinical Cancer Research.

[44]  B. Neel,et al.  The tyrosine phosphatase Shp2 (PTPN11) in cancer , 2008, Cancer and Metastasis Reviews.

[45]  E. Repasky,et al.  Growth and metastasis of surgical specimens of human breast carcinomas in SCID mice. , 1996, The cancer journal from Scientific American.

[46]  P G Pelicci,et al.  Nucleophosmin and its complex network: a possible therapeutic target in hematological diseases , 2011, Oncogene.

[47]  J. Pollard,et al.  A Paracrine Loop between Tumor Cells and Macrophages Is Required for Tumor Cell Migration in Mammary Tumors , 2004, Cancer Research.

[48]  S. Spiegel,et al.  The nuclear matrix protein, numatrin (B23), is associated with growth factor-induced mitogenesis in Swiss 3T3 fibroblasts and with T lymphocyte proliferation stimulated by lectins and anti-T cell antigen receptor antibody , 1988, The Journal of cell biology.

[49]  Robert A. Weinberg,et al.  Tumor Metastasis: Molecular Insights and Evolving Paradigms , 2011, Cell.

[50]  M. Huang,et al.  A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. , 2006, Experimental hematology.

[51]  Klaus Pantel,et al.  Circulating tumour cells in cancer patients: challenges and perspectives. , 2010, Trends in molecular medicine.

[52]  J. Segall,et al.  In vivo assay for tumor cell invasion. , 2009, Methods in molecular biology.

[53]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[54]  J. Condeelis,et al.  Arg/Abl2 promotes invasion and attenuates proliferation of breast cancer in vivo , 2012, Oncogene.

[55]  W. Gerald,et al.  Genes that mediate breast cancer metastasis to the brain , 2009, Nature.

[56]  J. Sparano,et al.  Clinical application of gene expression profiling in breast cancer. , 2010, Surgical oncology clinics of North America.

[57]  E. van Marck,et al.  Increased Serum Interleukin-8 in Patients with Early and Metastatic Breast Cancer Correlates with Early Dissemination and Survival , 2004, Clinical Cancer Research.

[58]  Ash A. Alizadeh,et al.  Gene Expression Signature of Fibroblast Serum Response Predicts Human Cancer Progression: Similarities between Tumors and Wounds , 2004, PLoS biology.

[59]  Bernard Ducommun,et al.  CDC25 phosphatases in cancer cells: key players? Good targets? , 2007, Nature Reviews Cancer.

[60]  Zhiyuan Hu,et al.  Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors , 2007, Genome Biology.

[61]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[62]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[63]  W. Guida,et al.  Discovery of a Novel Shp2 Protein Tyrosine Phosphatase Inhibitor , 2006, Molecular Pharmacology.

[64]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[65]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[66]  R. Beauchamp,et al.  A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers. , 2005, Neoplasia.

[67]  G. Sherlock,et al.  The prognostic role of a gene signature from tumorigenic breast-cancer cells. , 2007, The New England journal of medicine.

[68]  J. Fuxe,et al.  Transcriptional crosstalk between TGFβ and stem cell pathways in tumor cell invasion: Role of EMT promoting Smad complexes , 2010, Cell cycle.

[69]  L. Shaw,et al.  SHP2 Mediates the Localized Activation of Fyn Downstream of the α6β4 Integrin To Promote Carcinoma Invasion , 2010, Molecular and Cellular Biology.

[70]  J. Segall,et al.  A critical step in metastasis: in vivo analysis of intravasation at the primary tumor. , 2000, Cancer research.

[71]  J. Segall,et al.  The collection of the motile population of cells from a living tumor. , 2000, Cancer research.

[72]  A. Regev,et al.  An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors , 2008, Nature Genetics.

[73]  C. Daniel,et al.  Reversible inhibition of mammary gland growth by transforming growth factor-beta. , 1987, Science.

[74]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[75]  Eran Segal,et al.  Module map of stem cell genes guides creation of epithelial cancer stem cells. , 2008, Cell stem cell.

[76]  David Venet,et al.  Most Random Gene Expression Signatures Are Significantly Associated with Breast Cancer Outcome , 2011, PLoS Comput. Biol..

[77]  F. Bertucci,et al.  Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. , 2009, Cancer research.

[78]  E. Sahai,et al.  RHO–GTPases and cancer , 2002, Nature Reviews Cancer.

[79]  Ying Lin,et al.  Interleukin‐8 modulates growth and invasiveness of estrogen receptor‐negative breast cancer cells , 2007, International journal of cancer.

[80]  J. Condeelis,et al.  Breast Cancer Cells Isolated by Chemotaxis from Primary Tumors Show Increased Survival and Resistance to Chemotherapy , 2004, Cancer Research.

[81]  M. Daly,et al.  PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.

[82]  Stephen J. Elledge,et al.  Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop , 2012, Nature Medicine.

[83]  A. Lucas,et al.  IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells , 2003, Oncogene.

[84]  D. Lauffenburger,et al.  Mena invasive (MenaINV) promotes multicellular streaming motility and transendothelial migration in a mouse model of breast cancer , 2011, Journal of Cell Science.

[85]  Dennis B. Troup,et al.  NCBI GEO: archive for functional genomics data sets—10 years on , 2010, Nucleic Acids Res..

[86]  Larry Norton,et al.  Tumor Self-Seeding by Circulating Cancer Cells , 2009, Cell.

[87]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[88]  Alison Stopeck,et al.  Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  D. Birnbaum,et al.  CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. , 2010, The Journal of clinical investigation.

[90]  A. Partin,et al.  Monoclonal antibody to prostate cancer nuclear matrix protein (PRO:4‐216) recognizes nucleophosmin/B23 , 1999, The Prostate.

[91]  Andy J. Minn,et al.  Genes that mediate breast cancer metastasis to lung , 2005, Nature.

[92]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.